ALS drug gets rare second review at high-stakes FDA meeting

ALS drug gets rare second review at high-stakes FDA meeting

WASHINGTON — A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.

Patients and their families have rallied behind the drug from Amylyx Pharma, launching an aggressive lobbying campaign and enlisting members of Congress to push the Food and Drug Administration to grant approval.

The FDA has approved only two therapies for the disease, amyotrophic lateral sclerosis, which destroys nerve cells needed for basic functions like walking, talking and swallowing. One of these drugs is more likely to prolong your life span by several months.

In a rare act, FDA called a second meeting for neurology advisors. They narrowly voted against company’s drug. The panel was reviewing new statistical analyses from Amylyx and planned to vote again on whether to recommend approval. The FDA is not required to follow’s the group’s guidance.

A internal review prepared by FDA scientists ahead of the meeting struck an unfavorable tone. It concluded that the updated analysis from the company was “not persuasive” and contained “no new information.” However, the FDA instructed the panel to allow for greater regulatory flexibility in evaluating drugs for fatal diseases.

A final FDA decision is expected later this month.

Dr. Billy Dunn, FDA’s neurology review director, opened the meeting by noting the “concerns and limitations” with Amylyx’s data, while emphasizing the need for new treatment options.

“We are highly sensitive to the urgent need for the development of new treatments for ALS,” Dunn said. “We have not made any final decisions on the approvability of this application.”

Dunn also noted that a larger study being conducted by Amylyx could provide “more definitive results” on the drug by 2024.

In a highly unusual move, Dunn suggested the agency might be more willing to approve the drug if Amylyx would commit to withdrawing its medication if the 600-patient trial fails to show a benefit. Dunn then asked the co-founders of Amylyx to make a public commitment to this step. Justin Klee, Amylyx’s CEO and co-CEO stated that the company would withdraw the drug in such a scenario. The FDA is closely monitoring the ALS drug review to see if it is flexible in its reviews of experimental drugs for terminally ill patients and its resilience to outside pressure.

” We’re there because it’s very stressful,” Diana Zuckerman, a representative of the non-profit National Center for Health Research said in an interview before the meeting. “FDA is going the extra mile by saying you can have another meeting, but the company responded by giving them no new data.”

Amylyx conducted one small, mid-stage trial of its drug that showed some benefit in slowing the disease, but it was plagued by missing data and other problems, according to FDA reviewers.

“The final result — for a single study — is borderline and not very statistically persuasive,” FDA statistician Tristan Massie told panelists.

The Cambridge, Massachusetts, company says follow-up data gathered after the study showed the drug extended life. Patients who continued taking the drug survived about 10 months longer than patients who never took the drug, according to a new company analysis.

But FDA scientists said that the new approach “suffers from the same interpretability challenges” as the original study.

On Wednesday, more than 20 ALS researchers, patients and family members told the advisers they supported approval. The agency has also received more than 1,200 written comments, largely from ALS advocates. I’m asking for your approval because it works. It’s extending my life and I want that for others,” said Greg Canter, who was diagnosed with ALS in 2018 and participated in Amylyx’s study. The drug helped him improve his lung capacity, and slow down his functional decline.

Amylyx’s medication comes as a powder that combines two older drugs: one prescription medication for liver disorders and a dietary supplement used in traditional Chinese medicine.

Hanging over the review is FDA’s controversial approval of the Alzheimer’s drug Aduhelm last year, which was reviewed by the same agency scientists and outside advisers.

In that case, the FDA disregarded the overwhelmingly negative vote by its outside advisers, three of whom resigned over the decision. Congress and federal inspectors are investigating the approval of the agency, which was made following irregular meetings with Biogen.


Follow Matthew Perrone on Twitter: @AP_FDAwriter


The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

The post ALS drug gets rare second review at high-stakes FDA meeting appeared first on Associated Press.